Name | CRA-026440 hydrochloride |
Description | CRA-026440 hydrochloride is a potent and broad-spectrum HDAC inhibitor. CRA-026440 hydrochloride exhibits Ki values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM, respectively. CRA-026440 hydrochloride exhibits antitumor and antiangiogenic activities. |
In vitro | CRA-026440 hydrochloride exhibits anti-proliferation effect on HUVEC endothelial cells with GI50 of 1.41 μM. CRA-026440 hydrochloride leads to the accumulation of acetylated histone and acetylated tubulin, thus inhibiting the growth of tumor cells and inducing cell apoptosis. CRA-026440 hydrochloride inhibits angiogenesis in vitro in a dose-dependent manner[1]. |
In vivo | CRA-026440 hydrochloride (100 mg/kg; intravenous injection; daily; three consecutive days) resulted in a significant decrease in tumor growth in mice carrying HCT116 or U937 human tumor xenografts[1]. |
Storage | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (109.43 mM)
|
Keywords | CRA-026440 Hydrochloride | CRA026440 Hydrochloride | CRA 026440 Hydrochloride | 847460-34-8 Free base | 847460-34-8 |
Inhibitors Related | Valproic acid sodium salt | Panobinostat | Theophylline monohydrate | Sodium 4-phenylbutyrate | Vorinostat | Acefylline | Valproic Acid | Curcumin | Parthenolide | 4-Phenylbutyric acid | Theophylline | Methyl L-histidinate dihydrochloride |
Related Compound Libraries | Histone Modification Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |